US Stock MarketDetailed Quotes
BDRX Biodexa Pharmaceuticals
- 1.1900
- -0.0500-4.03%
Close May 17 16:00 ET
- 1.2400
- +0.0500+4.20%
Post 19:26 ET
5.22MMarket Cap-117P/E (TTM)
1.3700High1.1600Low487.46KVolume1.3700Open1.2400Pre Close622.74KTurnover23.14%Turnover RatioLossP/E (Static)4.38MShares16.320052wk High0.88P/B2.51MFloat Cap0.670052wk Low--Dividend TTM2.11MShs Float587200.0000Historical High--Div YieldTTM16.94%Amplitude0.6700Historical Low1.2770Avg Price1Lot Size
Biodexa Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | |
|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||
| Cash flow from continuing operating activities | 3.15%-6.83M | -17.31%-7.05M | 35.40%-6.01M | -9.3M | ||
| Net income from continuing operations | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -120.02%-22.19M | 32.90%-10.09M | ---15.03M |
| Operating gains losses | -6.59%-485K | 53.48%-455K | -275.27%-978K | --558K | ---- | ---- |
| Depreciation and amortization | -17.49%283K | -14.89%343K | -66.89%403K | --1.22M | ---- | ---- |
| Deferred tax | 51.20%-406K | -28.79%-832K | 49.57%-646K | 28.24%-1.28M | 12.16%-1.79M | ---2.03M |
| Other non cash items | -275.00%-42K | -45.45%24K | 33.33%44K | -94.02%33K | -5.64%552K | --585K |
| Change In working capital | -109.42%-49K | 184.28%520K | 60.40%-617K | -186.65%-1.56M | 223.74%1.8M | ---1.45M |
| -Change in receivables | 5,114.29%365K | 101.44%7K | -198.78%-487K | -32.00%493K | -29.61%725K | --1.03M |
| -Change in inventory | ---- | ---- | ---- | ---- | ---- | --347K |
| -Change in payables and accrued expense | -158.15%-207K | 373.85%356K | 93.51%-130K | ---2M | ---- | ---- |
| -Change in other working capital | -231.85%-207K | --157K | ---- | ---47K | ---- | ---- |
| Cash from discontinued investing activities | ||||||
| Operating cash flow | 3.15%-6.83M | -17.31%-7.05M | 35.40%-6.01M | -43.33%-9.3M | 51.75%-6.49M | ---13.45M |
| Investing cash flow | ||||||
| Cash flow from continuing investing activities | -20.45%-265K | 20.86%-220K | -110.80%-278K | 2.57M | ||
| Net PPE purchase and sale | 47.62%-22K | 84.89%-42K | -321.21%-278K | 78.71%-66K | -41.55%-310K | ---219K |
| Net intangibles purchase and sale | ---237K | --0 | --0 | ---- | ---9K | --0 |
| Net business purchase and sale | ---- | ---- | ---- | ---- | ---947K | ---- |
| Net other investing changes | 61.84%-79K | ---207K | ---- | 203.53%2.64M | -127.53%-2.55M | --9.26M |
| Cash from discontinued investing activities | ||||||
| Investing cash flow | -20.45%-265K | 20.86%-220K | -110.80%-278K | 167.61%2.57M | -142.10%-3.81M | --9.04M |
| Financing cash flow | ||||||
| Cash flow from continuing financing activities | 21,657.45%10.23M | -99.47%47K | 185.51%8.81M | 3.08M | ||
| Net issuance payments of debt | -5.62%-188K | 17.21%-178K | 96.52%-215K | -260.20%-6.18M | 166.29%3.86M | ---5.82M |
| Net common stock issuance | 4,190.95%10.43M | -97.31%243K | -7.26%9.04M | -30.95%9.74M | --14.11M | --0 |
| Cash dividends paid | --0 | --0 | --0 | --0 | ---- | ---- |
| Net other financing activities | ---- | ---- | ---- | -120.11%-229K | --1.14M | ---- |
| Cash from discontinued financing activities | ||||||
| Financing cash flow | 21,657.45%10.23M | -99.47%47K | 185.51%8.81M | -83.54%3.08M | 389.45%18.73M | ---6.47M |
| Net cash flow | ||||||
| Beginning cash position | -71.80%2.84M | 33.28%10.06M | -30.95%7.55M | 366.41%10.93M | -82.26%2.34M | --13.2M |
| Current changes in cash | 143.42%3.14M | -386.66%-7.22M | 169.15%2.52M | -143.18%-3.64M | 177.55%8.44M | ---10.88M |
| Effect of exchange rate changes | --0 | --0 | -103.07%-8K | 76.35%261K | 678.95%148K | --19K |
| End cash Position | 110.54%5.97M | -71.80%2.84M | 33.28%10.06M | -30.95%7.55M | 366.41%10.93M | --2.34M |
| Free cash flow | 0.30%-7.09M | -12.36%-7.11M | 33.46%-6.33M | -39.69%-9.51M | 50.28%-6.81M | ---13.69M |
| Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg